Malattia di Ollier e Sindrome di Maffucci: valutazione di nuovi marker diagnostici/prognostici

Title

Code

Ollier-Maffucci (OM)

Type

In Vitro

Start Year

2025

Status

In Corso

Principal Investigator

051-6366519, 051-6366681

luca.sangiorgi@ior.it

Sangiorgi Luca, MD

Director

Rare skeletal disorders

Operational unit that carry out the study

complex unit

Malattie rare scheletriche

Director

Sangiorgi Luca, MD

Go to the details >>

Documents and Videos attachament

Attachment

Nulla osta alla conduzione dello studio prot. Ollier-Maffucci (OM)

Tuesday 1 July 2025, 09:56

PG0007322_2025_Stampa_unica.pdf

You might also be interested in

Clinical Trial

A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

Clinical Trial

Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors

IRCCS

ISTITUTO ORTOPEDICO RIZZOLI

Malattia di Ollier e Sindrome di Maffucci: valutazione di nuovi marker diagnostici/prognostici

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in

Sito Web Istituto Ortopedico Rizzoli

Malattia di Ollier e Sindrome di Maffucci: valutazione di nuovi marker diagnostici/prognostici

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in